S&P Equity Research downgrades Bristol-Myers Squibb (NYSE: BMY) from Strong Buy to Buy.

S&P analyst, H. Saftlas, says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE